Purpose: To evaluate the safety and efficacy of retrieval of inferior vena cava filters (IVCF) temporarily placed in a suprarenal position. Methods: Retrieval of IVCF placed in a suprarenal position was performed in 13 patients (5 men and 8 women; mean age: 45.1 + 13.8 years) between July 2006 and May 2018 using either a loop snare technique or endobronchial forceps. Electronic medical records were reviewed for patient demographics and procedural information. Results: Inferior vena cava filters retrieved included Option Elite (n ¼ 9, 69%) and Günther Tulip (n ¼ 4, 31%). Caval thrombosis was not detected in any patients on pre-or postretrieval cavogram. Eleven suprarenal IVCF (84%) were retrieved during the first retrieval attempt after a median indwelling time of 1.8 months (range, 0.03-12.10 months). Retrieval was initially unsuccessful in 2 (16%) patients with Option Elite filters, but both were successfully removed on second attempt using endobronchial forceps. Thirteen suprarenal IVCF (100%) were ultimately retrieved. Conclusion: Endovascular retrieval of IVCF temporarily placed in a suprarenal position is safe and efficacious.
Introduction
Venous thromboembolism (VTE) is a common and significant cause of morbidity and mortality in hospitalized patients. 1, 2 Anticoagulation remains the gold standard for the treatment of VTE. 3 For high-risk patients requiring prophylaxis against VTE in whom anticoagulation is contraindicated, a retrievable inferior vena cava filter (IVCF) may be used to interrupt the inferior vena cava (IVC). 4 Most prior IVCF studies evaluated the outcomes of filter placement in and filter retrieval from the infrarenal IVC, where IVCF are labeled for use. 5 Placement of suprarenal IVCF is generally avoided because of the potential for complications including, but not limited to, IVCF migration due to the increased caliber of the suprarenal IVC and acute kidney injury if caval and subsequent bilateral renal vein thrombosis were to occur. [5] [6] [7] Intentional placement of IVCF in a suprarenal position is indicated for special patient populations. 8 Such situations include hypercoagulable patients with IVC anomalies (eg, duplicated IVC), pregnant patients at high risk for VTE, patients with infrarenal IVC narrowing due to thrombosis or external compression, and patients with renal vein or gonadal vein thrombosis. 6, 9 Although suprarenal IVCF placement in special patient populations is well described, 5, 7 little is known about endovascular retrieval of IVCF placed deliberately above the renal veins. The purpose of this study is to evaluate the safety and efficacy of retrieval of IVCF after intentional temporary placement in a suprarenal position.
Materials and Methods
This was a retrospective review of patients with IVCF that were placed in a suprarenal position and subsequently retrieved at a single institution between July 2006 and May 2018. We obtained institutional review board approval at the Icahn School of Medicine at Mount Sinai and the study was compliant with the rules and regulations set forth by the Health Insurance Portability and Accountability Act. A waiver for informed consent was granted as the data are blinded and retrospective.
Patient Selection
A system-wide search for all patients who had a procedural or radiologic report containing the keywords "suprarenal" and "filter" was performed. Close attention was paid to whether filters were intentionally placed in the suprarenal IVC. Only patients with IVCF placed in a suprarenal position that were subsequently retrieved using an endovascular technique were included in the study. If it was not explicitly stated that the filter was placed in a suprarenal position, the patient was excluded as it is possible for filters to have migrated from an infrarenal location. Eighty-four patients were found to have a known suprarenal IVCF on radiologic imaging (Figure 1 ). Of these patients, 28 patients were confirmed to have IVCF placed deliberately above the renal veins. Fifty-six of these patients had suprarenal IVCF on imaging but were excluded from the study because it could not be confirmed whether they were placed primarily or migrated from an infrarenal position. Of the 28 patients with IVCF placed in a suprarenal position, 14 patients underwent retrieval, while the remaining 14 patients were lost to follow-up and excluded. Of the 14 remaining patients, 13 underwent endovascular retrieval. One patient was excluded from the study due to IVC and duodenal perforation by the filter, which was removed using open surgical technique.
Data Collection and Analysis
Electronic medical records were reviewed in order to collect patient demographics and periprocedural information. Patient demographics included age at suprarenal IVCF placement, gender, pregnancy status, gestational age, primary diagnosis, history of VTE, and history of prior IVCF placement. Clinical and technical data collected included indications for IVCF placement, positioning, and retrieval; IVCF type; vascular access site; periprocedural complications; serum creatinine; suspected and/or confirmed presence of pulmonary embolism (PE); mean IVCF indwelling time; number of IVCF retrieval attempts; and whether IVCF retrieval was successful. Database creation and statistical analysis were performed using Microsoft Excel for Mac (version 15.26).
Procedure Description
Venous access for loop snare filter retrieval was obtained via the right internal jugular vein. A 5F pigtail catheter was advanced below the existing IVCF. Cavogram was performed to assess the IVC anatomy and status of the indwelling IVCF to be retrieved. After excluding caval thrombus, the 5F pigtail catheter was exchanged over a 0.035 guidewire for a 10F Arrow-flex sheath (Teleflex, Wayne, Pennsylvania), which was advanced to the level of the indwelling filter. An Amplatz Goose Neck snare (Medtronic, Minneapolis, Minnesota) was placed through the sheath, and the filter hook was snared and removed. For cases in which the filter could not be snared and removed, retrieval with endobronchial forceps (Lymol Medical, Woburn, Massachusetts) was used at a later date.
Results

Patient Demographics, Procedural Information, and Clinical Outcomes
Five (38%) men and 8 (62%) women were included in the study. Mean age at suprarenal IVCF placement was 45.1 + 13.8 years. Two patients were in the second trimester of pregnancy. Indications for filter placement, positioning, and retrieval are listed in Table 1 . Primary diagnoses of patients included in this study were hypercoagulable disorder (n ¼ 5), complication of pregnancy (VTE, n ¼ 1; intrapartum hemorrhage, n ¼ 1), malignancy (n ¼ 3), and inflammatory (ulcerative colitis, n ¼ 1; Behcet disease, n ¼ 1) or hematologic disorder (BuddChiari syndrome, n ¼ 1; Table 2 ). All patients had a history of VTE.
Inferior vena cava filters used included Option Elite filters (Argon Medical Devices, Inc, Athens, Texas; n ¼ 9, 69%) and Günther Tulip filters (Cook Medical Inc, Bloomington, Indiana; n ¼ 4, 31%). Transverse diameters (in centimeters) of infrarenal and suprarenal IVC prior to IVCF placement were measured using computed tomography (n ¼ 10), magnetic resonance (n ¼ 2), and venogram (n ¼ 1). Mean transverse diameters of infrarenal and suprarenal IVC prior to IVCF placement were 1.64 + 0.47 and 1.99 + 0.64, respectively (P ¼ .02). Vascular access sites for IVCF placement were right internal jugular vein (n ¼ 10, 77%), right common femoral vein (n ¼ 2, 15%), or the popliteal vein (n ¼ 1, 8%). There were no immediate periprocedural complications following suprarenal IVCF placement.
Follow-up serum creatinine was available for 7 (54%) patients. Mean serum creatinine before IVCF placement was 0.80 + 0.29 and mean serum creatinine 1 month following IVCF placement was 0.84 + 0.3. Pulmonary embolism was suspected and ruled out in 3 (23%) patients during the indwelling period. One long-term complication of suprarenal IVCF placement was noted in a patient who was found to have cranial IVCF migration into the intrahepatic IVC. The filter struts penetrated through the IVC wall and into the right hemidiaphragm, which resulted in a diaphragmatic hematoma (Figure 2 ). Of note, this patient had a failed initial filter retrieval attempt in March 2011, but returned for definitive retrieval in May 2018 after advanced retrieval techniques using endobronchial forceps had been adopted ( Figure 3) . As mentioned previously, in 1 patient who was excluded from this study, the filter struts penetrated the IVC and resulted in duodenal injury, which necessitated surgical removal.
Right internal jugular vein access was used for the initial IVCF retrieval attempt in all patients. Eleven (84%) suprarenal IVCF were retrieved during the first retrieval attempt using the loop snare technique after a median indwelling time of 1.8 months (range, 0.03-12.10 months). The first retrieval attempt failed in 2 (16%) patients with Option Elite filters, one in whom the filter hook could not be snared (placed 2.5 months prior) and another with incorporation of filter struts into the IVC wall (placed 11.6 months prior).
Advanced retrieval techniques were used for both patients who had unsuccessful initial retrieval attempts. Advanced retrieval techniques included endobronchial forceps retrieval via right internal jugular vein access in one patient and the transfemoral filter eversion technique via right common femoral vein access for the other. Filters were successfully retrieved using these techniques in both patients following indwelling periods of 5.3 and 98.9 months.
There were no periprocedural complications following suprarenal IVCF retrieval. Caval thrombosis was not detected in any patients on pre-or postretrieval inferior vena cavogram. Thirteen (100%) suprarenal IVCF were ultimately retrieved. 
Discussion
The findings of our study demonstrate the safety and efficacy of retrieving IVCF after intentional temporary placement in the suprarenal IVC in special patient populations. Following a short indwelling period, 11 (84%) of 13 IVCF placed in the suprarenal IVC were safely retrieved with no periprocedural complications. All 13 (100%) suprarenal IVCF included in this study were ultimately retrieved with 2 (16%) suprarenal IVCF needing a second procedure for successful removal using endobronchial forceps. Although infrarenal IVCF are placed more routinely, documented complications following infrarenal IVCF placement are similar to the possible complications of suprarenal IVCF placement. 5, 10 One of the potential complications associated with placement of any filter is filter migration. It has been proposed that the increased diameter of the suprarenal IVC may increase the risk of filter migration. 7 In a study of infrarenal filter placement, overall filter migration rates were 11%.
11 Similar findings were seen in a study of 73 patients with suprarenal IVCF, which reported 11 (15%) cases of caudal filter migration. 5 Despite concerns regarding increased risk of filter migration in the larger caliber suprarenal IVC, 12, 13 filter migration rates appear to be comparably low in Option Elite and Tulip filters placed both above and below the renal veins. Filter migration was only seen in 1 (8%) patient in our study, but this patient had a substantially longer indwelling time than the other patients in our study cohort. Perhaps if this filter was removed at an earlier date, migration may have been prevented.
A serious potential complication associated with suprarenal IVCF is acute kidney injury due to caval followed by bilateral renal vein thrombosis. 5, 7 While unilateral renal vein thrombosis has been seen as a complication of infrarenal IVCF, 14 bilateral occlusion of the renal veins is a genitourinary emergency. 15 Although the risk of this complication is theoretically higher with suprarenal IVCF if caval occlusion were to occur above the renal veins, studies of suprarenal IVCF have shown caval occlusion rates of 0-5%, 5, 16 which is comparable to caval occlusion rates of 4% seen in infrarenal IVCF studies. 5 Despite concerns of renal injury with caval occlusion, renal insufficiency occurred in 0 patients who were found to have caval occlusion following suprarenal IVCF placement in the former study. 5 Similarly, none of the patients in our study developed suprarenal IVC thrombosis with bilateral renal vein thrombosis or acute renal failure. The risk of bilateral renal vein thrombosis complicated by acute renal failure following suprarenal IVCF placement may be lower than previously thought.
An important long-term complication of IVCF is embedment of the filter into the IVC wall, which can result in more difficult filter retrieval, prolonged filter indwelling time, and the need for unconventional retrieval techniques. 17 In our study, 1 of the 2 initial retrieval failures was due to cranial filter migration with extensive incorporation of the filter struts into the intrahepatic IVC wall. The filter was unable to be retrieved with the loop snare technique, which led to a filter indwelling time of approximately 8 years. During this protracted indwelling period, the filter penetrated through the intrahepatic cava and into the right diaphragmatic crus, causing a diaphragmatic hematoma. Aggressive retrieval techniques using rigid endobronchial forceps have since been increasingly used to overcome the limitations of the loop snare technique in complex filter retrieval. 18 Filter retrieval with endobronchial forceps appears to be a reasonable option for retrieving filters in the suprarenal IVC when the loop snare technique fails.
Both retrieval failures that occurred in our study took place when attempting to retrieve an Option Elite filter (Argon Medical Devices, Inc). In a study comparing filter types, 7.7% of Option filters were noted to have tilted within the IVC, 19 which is a known factor contributing to difficult filter retrieval. [20] [21] [22] In a larger prospective study, retrieval failure occurred with 3 (8%) of the 39 infrarenal Option Elite filters. 23 In complex cases, endobronchial forceps can be used for filter retrieval. After advancing endobronchial forceps through a sheath from the right internal jugular vein to just superior to the filter, the filter hook can be grasped by the forceps and retrieved through the jugular access site. 18 Another innovative technique, known as transfemoral filter eversion, involves using endobronchial forceps through femoral access to evert the Option Elite filter caudally so that the filter can be removed through a common femoral vein sheath. Posham et al demonstrated a 100% success rate when using the transfemoral filter eversion technique to remove 25 Option Elite filters that had failed initial retrieval with a loop snare technique. 24 As novel techniques for retrieval emerge, leaving an IVCF in situ when the indication for caval interruption no longer exists may become less common.
Our study has several limitations. This was a single-center, retrospective study with a small cohort. Future studies should aim to include multiple hospital centers and a larger, more diverse patient population. Not all patients had consistent reporting of laboratory values, such as serum creatinine, following IVCF placement, nor did they have systematic followup radiologic imaging. Lack of adequate radiographic followup may lead to underreporting of clinically inert complications. A standardized approach to radiographic monitoring of IVCF would decrease ambiguity, would make it easier to evaluate for indolent complications, and would improve filter retrieval awareness and planning.
Conclusion
Temporary placement and endovascular retrieval of IVCF placed intentionally in a suprarenal position is safe and efficacious. Protracted indwelling times may lead to significant complications. Future studies directly comparing infrarenal versus suprarenal IVCF can help to define guidelines for filter positioning, placement, and retrieval.
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